Administration Intravesical Antibiotics Antineoplastic/administration & dosage/*therapeutic use BCG Vaccine Carcinoma Transitional Cell/*drug therapy Humans Mitomycin/administration & dosage/*therapeutic use Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Administration Intravesical BCG Vaccine/therapeutic use *Carcinoma in Situ/diagnosis/therapy Female Humans Male Neoplasm Invasiveness *Urinary Bladder Neoplasms/diagnosis/pathology/therapy *Urology *BCG unresponsive *Bacillus Calmette-Guerin (BCG) *Bladder cancer *Cystoscopy *Diagnosis *European Association of Urology (EAU) *Follow-up *Guidelines *Intravesical chemotherapy *Prognosis *Radical cystectomy *Transurethral resection (TUR) *Urothelial carcinoma

Adjuvants Immunologic/adverse effects Administration Intravesical BCG Vaccine/adverse effects Humans *Urinary Bladder Neoplasms/drug therapy *Urology Antibiothérapie Antibiotic therapy BCG therapy BCG thérapie Bladder Carcinome urothélial Complications Endovesical instillations Instillations endovésicales Nmibc Tvnim Urothelial carcinoma Vessie

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

Adjuvants Immunologic Cystectomy Humans *Kidney Transplantation/adverse effects Risk Factors *Urinary Bladder Neoplasms/epidemiology Bcg Bladder cancer Cáncer vesical Kidney transplantation Trasplante renal

Adjuvants Immunologic/administration & dosage Administration Intravesical BCG Vaccine/*adverse effects Chondroitin Sulfates/*administration & dosage Cystitis/chemically induced/pathology/*prevention & control Humans Hyaluronic Acid/*administration & dosage Immunotherapy/*adverse effects Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/pathology/*therapy

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Adjuvants Immunologic/*administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Humans Instillation Drug Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin Maintenance therapy Non-muscle-invasive bladder cancer Progression Recurrence

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Asymptomatic Diseases BCG Vaccine/*administration & dosage/adverse effects Bacteriuria/*complications/diagnosis Humans Immunotherapy/adverse effects/*methods Neoplasm Invasiveness Risk Assessment Treatment Outcome Urinary Bladder Neoplasms/complications/*drug therapy/immunology/pathology Bacillus Calmette-Guerin Bacteriuria Bladder cancer Intravesical instillation

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Administration Intravesical BCG Vaccine/therapeutic use Disease Progression Female Humans *Ki-67 Antigen Male *Neoplasm Invasiveness Prognosis Prospective Studies *Urinary Bladder Neoplasms/diagnosis/drug therapy/pathology Ki67 meta-analysis non-muscular-invasive bladder cancer

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Adjuvants Immunologic/administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Bayes Theorem Disease Progression Humans Immunotherapy/*methods Incidence Neoplasm Recurrence Local/drug therapy Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy Intravesical bacillus Calmette–Guerin efficacy maintenance non-muscle-invasive bladder cancer side effects

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Antibiotics Antineoplastic/*therapeutic use BCG Vaccine/*therapeutic use Combined Modality Therapy Humans Mitomycin/*therapeutic use Urinary Bladder Neoplasms/*drug therapy bacillus Calmette-Guérin mitomycin C non-muscle-invasive bladder carcinoma recurrence rate meta-analysis.

Adjuvants Immunologic/*therapeutic use BCG Vaccine/*therapeutic use Humans Mycobacterium bovis Urinary Bladder Neoplasms/*drug therapy/pathology BCG vaccine immunotherapy urinary bladder neoplasms

BCG Vaccine/*adverse effects/immunology/therapeutic use C-Reactive Protein/analysis Cancer Vaccines/*adverse effects/immunology/therapeutic use Databases Factual Dysuria/etiology Humans Lymphadenopathy/etiology Pneumonia/etiology Skin Ulcer/etiology Tuberculosis Vaccines/*adverse effects/immunology Urinary Bladder Neoplasms/*therapy

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy